共 50 条
- [31] Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorderNEUROPSYCHOPHARMACOLOGY, 2019, 44 (13) : 2268 - 2276Thase, Michael E.Stanford, Arielle D.Memisoglu, AsliMartin, WilliamClaxton, AmyBodkin, J. AlexanderTrivedi, Madhukar H.Fava, MaurizioYu, MiaoPathak, Sanjeev
- [32] Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN studyCURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (05) : 731 - 742Pozo-Rosich, PatriciaDetke, Holland C.Wang, ShufangDolezil, DavidLi, Lily Q.Aurora, Sheena K.Reuter, Uwe
- [33] Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgiaARTHRITIS RESEARCH & THERAPY, 2013, 15 (06)Spaeth, MichaelAlegre, CayetanoPerrot, SergeWang, Youyu GraceGuinta, Diane R.Alvarez-Horine, SarahRussell, Irwin Jon
- [34] Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 studyJOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (01) : 43 - 50Frost, AdaaniJanmohamed, MunirFritz, Jason S.McConnell, John W.Poch, DavidFortin, Terry AnnMiller, Chad E. gChin, Kelly M.Fisher, MicahEggert, MichaelMcEvoy, ColleenBenza, Raymond L.Farber, Harrison W.Kim, Nick H.Pfister, ThomasShiraga, YokoMcLaughlin, Vallerie
- [35] Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineCEPHALALGIA, 2019, 39 (11) : 1455 - 1464Ashina, MessoudGoadsby, Peter J.Reuter, UweSilberstein, StephenDodick, DavidRippon, Gregory A.Klatt, JanXue, FeiChia, VictoriaZhang, FengCheng, SunfaMikol, Daniel D.
- [36] Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extensionJOURNAL OF NEUROMUSCULAR DISEASES, 2025, : 231 - 243Habib, Ali A.Druzdz, ArturGrosskreutz, JulianMantegazza, RenatoSacconi, SabrinaUtsugisawa, KimiakiVu, TuanVissing, JohnGayfieva, MaryamPulido-Valdeolivas, IreneTarancon, ThaisWoltering, FranzBril, Vera
- [37] Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension StudyJOURNAL OF CROHNS & COLITIS, 2021, 15 (12) : 2001 - 2010Ferrante, MarcFeagan, Brian G.Panes, JulianBaert, FilipLouis, EdouardDewit, OlivierKaser, ArthurDuan, W. RachelPang, YinuoLee, Wan-JuGustafson, DawnLiao, XiaomeiWallace, KoriKalabic, JasminaD'Haens, Geert R.
- [38] Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trialEPILEPSIA, 2021, 62 (10) : 2505 - 2517Scheffer, Ingrid E.Halford, Jonathan J.Miller, IanNabbout, RimaSanchez-Carpintero, RocioShiloh-Malawsky, YaelWong, MatthewZolnowska, MartaChecketts, DanielDunayevich, EduardoDevinsky, Orrin
- [39] Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension studyCNS SPECTRUMS, 2016, 21 (05) : 393 - 402Correll, Christoph U.Cucchiaro, JosephineSilva, RobertHsu, JayPikalov, AndreiLoebel, Antony
- [40] BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertensionPULMONARY CIRCULATION, 2022, 12 (02)Spikes, Leslie A.Bajwa, Abubakr A.Burger, Charles D.Desai, Sapna, VEggert, Michael S.El-Kersh, Karim A.Fisher, Micah R.Johri, ShilpaJoly, Joanna M.Mehta, JineshPalevsky, Harold, IRamani, Gautam, VRestrepo-Jaramillo, RicardoSahay, SandeepShah, Trushil G.Deng, ChunqinMiceli, MelissaSmith, PeterShapiro, Shelley M.